Compare APPS & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPS | INVA |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2012 | 2000 |
| Metric | APPS | INVA |
|---|---|---|
| Price | $10.87 | $21.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.25 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 3.9M | 646.6K |
| Earning Date | 06-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 62.92 | ★ 816.67 |
| EPS | N/A | ★ 1.25 |
| Revenue | $103,569,000.00 | ★ $217,217,000.00 |
| Revenue This Year | $15.60 | $8.95 |
| Revenue Next Year | $11.34 | $12.65 |
| P/E Ratio | ★ N/A | $16.81 |
| Revenue Growth | 38.55 | ★ 62.63 |
| 52 Week Low | $2.74 | $16.52 |
| 52 Week High | $15.34 | $25.15 |
| Indicator | APPS | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.67 | 48.12 |
| Support Level | $3.82 | $20.44 |
| Resistance Level | $13.60 | $22.02 |
| Average True Range (ATR) | 1.10 | 0.51 |
| MACD | -0.21 | 0.09 |
| Stochastic Oscillator | 29.33 | 48.94 |
Digital Turbine Inc is an independent mobile growth platform that levels up the landscape for advertisers, publishers, carriers, and device original equipment manufacturers. The Company offers end-to-end products and solutions leveraging proprietary technology to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. In addition, its products and solutions provide monetization opportunities for OEMs, carriers, and application (app or apps) publishers and developers.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.